| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 641 | 2017 |
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 … SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ... The Lancet Oncology 21 (4), 519-530, 2020 | 598 | 2020 |
| Delays in diagnosis and treatment of breast cancer: a multinational analysis J Jassem, V Ozmen, F Bacanu, M Drobniene, J Eglitis, KC Lakshmaiah, ... The European journal of public health 24 (5), 761-767, 2014 | 170 | 2014 |
| Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial J Ocvirk, T Brodowicz, F Wrba, TE Ciuleanu, G Kurteva, S Beslija, I Koza, ... World journal of gastroenterology: WJG 16 (25), 3133, 2010 | 138 | 2010 |
| Role of Ki-67 as a prognostic factor in gastrointestinal stromal tumors B Belev, I Brčić, J Prejac, ZA Golubić, D Vrbanec, J Božikov, I Alerić, ... World journal of gastroenterology: WJG 19 (4), 523, 2013 | 97 | 2013 |
| Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European … C Zielinski, S Beslija, Z Mrsic-Krmpotic, M Welnicka-Jaskiewicz, ... Journal of clinical oncology 23 (7), 1401-1408, 2005 | 79 | 2005 |
| FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II … T Brodowicz, TE Ciuleanu, D Radosavljevic, E Shacham-Shmueli, ... Annals of oncology 24 (7), 1769-1777, 2013 | 70 | 2013 |
| Single-nucleotide polymorphisms in genes encoding toll-like receptor-2,-3,-4, and-9 in case–control study with breast cancer GE Etokebe, J Knežević, B Petričević, J Pavelić, D Vrbanec, Z Dembić Genetic Testing and Molecular Biomarkers 13 (6), 729-734, 2009 | 62 | 2009 |
| Prognostic value of different factors in breast carcinoma L Hlupić, J Jakić-Razumović, J Božikov, M Ćorić, B Belev, D Vrbanec Tumori Journal 90 (1), 112-119, 2004 | 60 | 2004 |
| Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study … J Gligorov, B Ataseven, M Verrill, M De Laurentiis, KH Jung, HA Azim, ... European Journal of Cancer 82, 237-246, 2017 | 51 | 2017 |
| Single nucleotide polymorphism in the interleukin 12B gene is associated with risk for breast cancer development MH Kaarvatn, J Vrbanec, A Kulic, J Knezevic, B Petricevic, S Balen, ... Scandinavian journal of immunology 76 (3), 329-335, 2012 | 51 | 2012 |
| A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low-and … Y Belkacemi, N Grellier, S Ghith, K Debbi, G Coraggio, A Bounedjar, ... European Journal of Cancer 135, 130-146, 2020 | 45 | 2020 |
| Nm23 gene product expression in invasive breast cancer B Belev, I Alerić, D Vrbanec, M Petroveceki, J Unušic, J Jakić-Razumović Acta Oncologica 41 (4), 355-361, 2002 | 45 | 2002 |
| Expression of Toll-like receptor 4 and beta 1 integrin in breast cancer B Petricevic, D Vrbanec, J Jakic-Razumovic, I Brcic, D Rabic, T Badovinac, ... Medical Oncology 29, 486-494, 2012 | 37 | 2012 |
| Autocrine tumour growth regulation by somatomedin C: an in-vitro model K Pavelić, D Vrbanec, S Marušić, S Levanat, T Čabrijan Journal of endocrinology 109 (2), 233-238, 1986 | 37 | 1986 |
| Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients A Kulić, M Sirotković-Skerlev, S Jelisavac-Ćosić, D Herceg, Z Kovač, ... Medical oncology 27, 887-893, 2010 | 34 | 2010 |
| FOLFOX4 plus cetuximab for patients with previously untreated metastatic colorectal cancer according to tumor RAS and BRAF mutation status: updated analysis of the CECOG/CORE 1 … K Kaczirek, TE Ciuleanu, D Vrbanec, E Marton, D Messinger, ... Clinical colorectal cancer 14 (2), 91-98, 2015 | 33 | 2015 |
| Telomerase activity in breast cancer patients: association with poor prognosis and more aggressive phenotype A Kulić, ND Plavetić, S Gamulin, J Jakić-Razumović, D Vrbanec, ... Medical Oncology 33, 1-6, 2016 | 32 | 2016 |
| Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses T Brodowicz, I Láng, Z Kahán, R Greil, S Beslija, SM Stemmer, B Kaufman, ... British journal of cancer 111 (11), 2051-2057, 2014 | 32 | 2014 |
| Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer C Zielinski, I Lang, S Beslija, Z Kahan, MJ Inbar, SM Stemmer, R Anghel, ... British Journal of Cancer 114 (2), 163-170, 2016 | 31 | 2016 |
